INDEPENDENT NEWS

Geneious Biologics annotation algorithm beats IgBLAST, MiXCR

Published: Thu 3 May 2018 09:44 AM
Geneious Biologics annotation algorithm beats IgBLAST, MiXCR says new white paper
AUCKLAND, NZ – May 2, 2018 – A white paper released today shows an annotation algorithm developed for Geneious Biologics, a commercial software solution for antibody screening and discovery, outperforms those of open source sequence analysis software IgBLAST and MiXCR.
The white paper outlines why accurate antibody sequence annotation is important for companies undertaking therapeutic antibody research. Biologic drug development involves increasingly large volumes of antibody sequence data. This introduces core problems around accurately screening huge numbers of candidate sequences to identify the most promising, in usefully short timescales.
In a series of comparative tests, MiXCR 2.1.9, IgBLAST and Geneious Biologics annotation algorithms were tasked with analyzing the same dataset - National Center for Biotechnology Information (NCBI) reference database SRR5754964 (Human).
Evaluating accuracy of sequence annotation is difficult due to a lack of industry gold standard data sets, however, compared with IgBLAST and MiXCR, Geneious Biologics’ performance in annotating CDR regions and germline genes correlates most closely with consensus results of the three algorithms. In rare cases where Geneious Biologics disagreed with consensus results, bioinformaticians closely reviewed the result and determined that Geneious Biologics was generally correct while both MiXCR and IgBLAST were incorrect, indicating superior performance of Geneious Biologics over these popular open source tools.
“Speed and accuracy is absolutely fundamental for organizations undertaking highly specific research to identify and validate potential therapeutic antibody candidates,” said white paper author and Vice President, Geneious Biologics Solutions, Jannick Bendtsen, PhD.
“Few existing software providers offer solutions with the power to meet speed and accuracy requirements of specialist therapeutic antibody researchers. For that reason we invest heavily in development to ensure Geneious Biologics delivers best-in-class technology to accelerate therapeutic antibody discovery,” Dr Bendtsen said.
Download the white paper - Powerful bioinformatic support for specialized therapeutic antibody discovery.
About Geneious Biologics
Geneious Biologics is a next generation cloud software solution purpose-built, in collaboration with industry partners, for commercial antibody discovery and screening. Delivered through a modern intuitive, user-friendly web interface, the platform provides a fully managed data platform and informatics system in a secure cloud computing infrastructure. For more information about Geneious Biologics visit www.geneiousbiologics.com.
ends

Next in Business, Science, and Tech

RBNZ To Implement $30bn Large Scale Asset Purchase Programme Of NZ Govt Bonds
By: The Reserve Bank of New Zealand
Monetary Policy With Very Low Interest Rates
By: The Reserve Bank of New Zealand
More Snow On Glaciers But No Good News, Say Scientists
By: NIWA
Elevate NZ Venture Fund To Lift Productivity
By: New Zealand Government
New Legislation To Boost Organics
By: New Zealand Government
Misinformation Circulating On Biodiversity Policy
By: Forest And Bird
Govt Backs RBNZ Move To Support Economy With Lower Interest Rates
By: New Zealand Government
Reserve Bank announces further measures to support economy
By: RNZ
Holding Off The COVID-19 Recession – Expert Reaction
By: Science Media Centre
Banking Sector Prepared For Responding To COVID-19
By: The Reserve Bank of New Zealand
Reserve Bank’s ‘unconventional Tools’ Are Conventional Elsewhere
By: Social Credit
RBNZ Survey: Experts Say An Out-of-cycle Rate Cut May Cause Panic
By: Finder
Next Steps Of Govt And Business COVID-19 Response
By: New Zealand Government
NZX falls following US interest rate cut
By: RNZ
Coronavirus and the economy: Responding to Covid-19 with precision
By: RNZ
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media